SecBot SecBot

PLUR

Pluri Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0001158780 Biotech & Drug Discovery
$1.13 +0.14 (+14.14%)
Oct 26 4:00 PM ET · prev $0.9900
Market cap
$13.6M
Nano cap
Median target
$12.00
+962% · range $12.00–12.00
Next earnings
Nov 10
in 15 days
1 year
−71.0%
from $3.90 · Oct 27
30 days
+16.5%
from $0.9700
52-week range
$0.8500–4.45
−75% from high · low Oct 19
Avg volume 20D
39.8K
Oct 26 spike 454.0K
Short interest
19.3K
≈0.1% of shares · −3.0%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 4 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/7 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH Pluri Inc. issued 833,334 common shares at $1.50/share and a warrant for 833,334 shares at $1.65/share to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −3.0% to 19.3K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED1,918$4.0K
CITIGROUP INCNEAR_EXIT191$393.00
CITIGROUP INCDOUBLED1,360$4.6K
UBS Group AGDOUBLED95$322.00
RENAISSANCE TECHNOLOGIES LLCTRIM20,024$59.9K
BANK OF AMERICA CORP /DE/DOUBLED125$374.00
BANK OF AMERICA CORP /DE/NEAR_EXIT47$211.00
UBS Group AGTRIM18$81.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +962%.Targets as of Jun 18, 2026.

Recent actions
DateFirmActionRating
Jun 2, 2025Alliance Global Partners
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 20, 2026
SHORRER DORON
Director
AWARD31,569 sh
Aug 20, 2026
Manieu Alexandre Weinstein
Director
AWARD180,000 sh
Jun 30, 2026
Manieu Alexandre Weinstein
Director
AWARD641 sh
Jun 30, 2026
Manieu Alexandre Weinstein
Director
EXPIRED625,000 sh
Apr 21, 2026
Manieu Alexandre Weinstein
Director
AWARD$625.0K
Apr 21, 2026
Manieu Alexandre Weinstein
Director
AWARD$625.0K
Mar 31, 2026
Manieu Alexandre Weinstein
Director
AWARD$625.0K
Mar 31, 2026
Manieu Alexandre Weinstein
Director
AWARD$625.0K

Earnings setup

Estimates
Nov 10
reports in 15 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
19,310
shares short
-3.0%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Pluri Inc. issued 833,334 common shares at $1.50/share and a warrant for 833,334 shares at $1.65/share to its chairman…
8-K — Impact 5/10
Oct 16, 2026 SEC
The SEC declared effective Pluri Inc.'s S-1 registration statement (File No. 333-299324) on October 15, 2026. This…
EFFECT — Impact 5/10
Oct 6, 2026 SEC
Pluri Inc. filed an S-1 registration statement to register 2,228,940 common shares for resale by Armistice Capital…
S-1 — Impact 3/10
Sep 15, 2026 Earnings calendar
PLUR Q4 2026 Earnings After Market Close — 2026-09-15
Aug 20, 2026 Insider
SHORRER DORON was granted 31,569 shares
Director
Aug 20, 2026 Insider
Manieu Alexandre Weinstein was granted 180,000 shares
Director
Aug 17, 2026 Press
Pluri's majority-owned food-tech subsidiary, Ever After Foods (EAF), has acquired Fishway BV, a Belgian aquatic cell…
Impact 4/10
Jun 30, 2026 Insider
Manieu Alexandre Weinstein was granted 641 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
PLUR Q1 2027 Earnings Scheduled — 2026-11-10
Recent
Sep 15, 2026
Earnings date
PLUR Q4 2026 Earnings After Market Close — 2026-09-15
Aug 17, 2026
M&A
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence…
Jul 28, 2026
Press release
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
Pluri’s subsidiary Cellav, has completed a cosmetic regulatory registration and notification process in the UK, supporting coming commercial launch
Jul 15, 2026
Listing
Listing Status: PLUR — Deficient (was Normal)
Pluri Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
May 11, 2026
Earnings date
PLUR Q3 2026 Earnings Scheduled — 2026-05-11

SecBot reports

9 filings · 1 press release · 0 bullish · 5 bearish · 1 mixed · 3 neutral
All PLUR filing & press-release reports (10)